Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Medical Oncology · Malignant Neoplasm of Upper-Outer Quadrant of Female Breast

Systemic Therapies and Radiation: Treating the Whole Body

At a Glance

Treatment for upper-outer breast cancer is tailored to the tumor’s receptor results, stage, menopausal status, and overall health. Medicines treat cancer throughout the body, while radiation helps prevent cancer from returning in the breast or nearby lymph nodes.

While surgery removes the cancer you can see, systemic therapies and radiation are the strategies used to treat your entire body and prevent the cancer from returning. These treatments are highly individualized, guided by your tumor’s biology (its receptors and grade), its stage, your menopausal status, and your overall health [1][2].

Systemic Therapies: Treating the Whole Body

Systemic treatments circulate through your bloodstream to reach cancer cells wherever they may be.

1. Chemotherapy

Chemotherapy uses powerful drugs to kill rapidly dividing cells.

  • Timing: You may receive neoadjuvant therapy (before surgery) or adjuvant therapy (after surgery) [1].
  • When It Is Used: Chemotherapy is frequently used for higher-risk early-stage Triple Negative Breast Cancer (TNBC) and HER2-positive cancers [3][2]. For selected higher-risk early TNBC, the immunotherapy drug pembrolizumab may be added to chemotherapy [4]. However, small, node-negative tumors may warrant less intensive regimens.
  • Pathologic Complete Response (pCR): If you have neoadjuvant therapy, doctors can see how the tumor responds. Finding no active cancer at the time of surgery (a pCR) is an excellent prognostic sign, though it is not an absolute guarantee of a cure [5][6].

2. Targeted Therapy for HER2+ Disease

If your tumor is HER2-positive, targeted drugs like trastuzumab (and sometimes pertuzumab, depending on risk) are used to “lock onto” the HER2 protein and shut down growth signals [7][2].

  • Adjusting the Plan: If you receive neoadjuvant therapy but cancer cells remain at the time of surgery, your doctor may switch you to a different drug, such as ado-trastuzumab emtansine (T-DM1), to further reduce the risk of recurrence [6].

3. Endocrine (Hormone) Therapy

For HR-positive (ER+ or PR+) tumors, hormone therapy is the most critical long-term treatment, typically taken for 5 to 10 years [8][9].

  • Tamoxifen: Often used in premenopausal women, this drug blocks estrogen from binding to cancer cells [10].
  • Aromatase Inhibitors (AIs): These lower the amount of estrogen made in tissues (like fat and muscle). Because they do not reliably suppress the ovaries, AIs are generally used only in postmenopausal women, or in premenopausal women who are also receiving medication or surgery for ovarian suppression [10][11].
  • Duration and Side Effects: Extending therapy beyond 5 years is individualized based on your risk and tolerance of side effects (like joint pain or hot flashes). Ovarian suppression carries its own side effects, including sudden menopause and fertility implications [12][13].

Radiation Therapy: Local Reinforcement

Radiation uses high-energy beams to destroy any microscopic cancer cells remaining in the breast or surrounding areas.

  • After Lumpectomy: Standard care almost always includes whole-breast irradiation to prevent local recurrence [14].
  • After Mastectomy (PMRT): Post-mastectomy radiation is not automatic. The decision depends on tumor size, margins, skin involvement, the number of positive lymph nodes, and response to neoadjuvant therapy [15][16].
  • Regional Nodal Irradiation (RNI): This targets the lymph nodes near the collarbone and armpit [17]. In some carefully selected cases, RNI can be used instead of an Axillary Lymph Node Dissection (ALND) [18][19]. However, the choice is complex, and RNI itself can contribute to lymphedema and incidental heart or lung exposure.

Managing Side Effects and Health

Because these treatments are powerful, your team will actively monitor your long-term health:

  • Heart Health: HER2-targeted therapies and certain chemotherapies (anthracyclines) can affect heart function; you may have regular echocardiograms to monitor this [6].
  • Bone Health: Aromatase inhibitors and ovarian suppression can accelerate bone loss. Your doctor will monitor you with DXA scans (bone density tests) and may recommend bone-strengthening medications [20][21]. Do not start supplements without discussing them with your care team.

Common questions in this guide

How is treatment for upper-outer breast cancer chosen?
Your plan is based on estrogen and progesterone receptor results, HER2 status, tumor grade and stage, menopausal status, and overall health. It may include chemotherapy, HER2-targeted medicine, hormone therapy, immunotherapy for selected higher-risk triple-negative cancers, radiation, and surgery.
Will chemotherapy happen before or after breast cancer surgery?
Chemotherapy can be given before surgery to shrink the cancer and show how it responds, or after surgery to destroy remaining microscopic cancer cells. The best timing depends on the tumor’s biology, stage, and your overall treatment plan.
Is radiation needed after breast cancer surgery?
Whole-breast radiation is standard after lumpectomy in most cases. After mastectomy, radiation is considered based on tumor size, surgical margins, skin involvement, lymph nodes, and response to treatment before surgery.
What does a complete response after treatment before surgery mean?
If no active cancer is found at surgery after treatment given before surgery, this is called a pathologic complete response and is a favorable prognostic sign. It lowers concern about recurrence but does not guarantee a cure.
How long will hormone therapy last for hormone receptor-positive breast cancer?
Hormone therapy often continues for 5 to 10 years. Tamoxifen is commonly used before menopause, while aromatase inhibitors are generally used after menopause or with ovarian suppression before menopause; duration balances recurrence risk and side effects.
How will treatment affect my heart and bones?
HER2-targeted drugs and some chemotherapy can weaken heart function, so echocardiograms may be used for monitoring. Aromatase inhibitors and ovarian suppression can accelerate bone loss, so DXA scans and, when appropriate, bone-strengthening medicines may be recommended.
Can radiation to the lymph nodes replace a full lymph node dissection?
In selected patients, regional nodal irradiation may be considered instead of axillary lymph node dissection. The decision depends on lymph node findings and the rest of the treatment plan because radiation can also increase lymphedema risk and expose nearby heart or lung tissue.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my tumor's biology (ER/PR/HER2 status) and stage, which specific systemic treatments are recommended for me?
  2. 2.Will I start with chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant), and what are the advantages for my case?
  3. 3.If my sentinel node biopsy shows cancer, am I a candidate for regional nodal irradiation (RNI) instead of a full node dissection?
  4. 4.How will you monitor my heart health and bone density during my targeted or endocrine therapy?
  5. 5.What is my predicted risk of recurrence, and how does my menopausal status influence my endocrine therapy choices?
  6. 6.If I have residual cancer after neoadjuvant treatment, how will that change my adjuvant treatment plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

    Korde LA, Somerfield MR, Carey LA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(13)):1485-1505 doi:10.1200/JCO.20.03399.

    PMID: 33507815
  2. 2

    Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.

    Harbeck N

    Breast (Edinburgh, Scotland) 2022; (62 Suppl 1()):S12-S16 doi:10.1016/j.breast.2022.01.006.

    PMID: 35148934
  3. 3

    Pembrolizumab for Early Triple-Negative Breast Cancer.

    Schmid P, Cortes J, Pusztai L, et al.

    The New England journal of medicine 2020; (382(9)):810-821 doi:10.1056/NEJMoa1910549.

    PMID: 32101663
  4. 4

    Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

    Schmid P, Cortes J, Dent R, et al.

    The New England journal of medicine 2022; (386(6)):556-567 doi:10.1056/NEJMoa2112651.

    PMID: 35139274
  5. 5

    Neoadjuvant treatment for HER2-positive breast cancer.

    Takada M, Toi M

    Chinese clinical oncology 2020; (9(3)):32 doi:10.21037/cco-20-123.

    PMID: 32527117
  6. 6

    Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

    von Minckwitz G, Huang CS, Mano MS, et al.

    The New England journal of medicine 2019; (380(7)):617-628 doi:10.1056/NEJMoa1814017.

    PMID: 30516102
  7. 7

    Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

    von Minckwitz G, Procter M, de Azambuja E, et al.

    The New England journal of medicine 2017; (377(2)):122-131 doi:10.1056/NEJMoa1703643.

    PMID: 28581356
  8. 8

    Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer.

    Bracken-Clarke DB, Lucas MW, Higgins MJ

    Breast care (Basel, Switzerland) 2017; (12(3)):138-144 doi:10.1159/000477956.

    PMID: 28785180
  9. 9

    Optimal extension time after initial endocrine therapy for postmenopausal hormone receptor-positive early-stage breast cancer: a systematic review and meta-analysis.

    Ying Z, Linxun L, Kechang Z, et al.

    BMC women's health 2025; (25(1)):156 doi:10.1186/s12905-025-03610-9.

    PMID: 40181354
  10. 10

    Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

    Lancet (London, England) 2015; (386(10001)):1341-1352 doi:10.1016/S0140-6736(15)61074-1.

    PMID: 26211827
  11. 11

    Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

    Burstein HJ, Lacchetti C, Anderson H, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(14)):1689-701 doi:10.1200/JCO.2015.65.9573.

    PMID: 26884586
  12. 12

    Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?

    Walsh EM, Nunes R, Wilkinson MJ, Santa-Maria CA

    Current oncology reports 2020; (22(12)):123 doi:10.1007/s11912-020-00988-7.

    PMID: 33015752
  13. 13

    Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.

    Frampton JE

    Drugs 2017; (77(18)):2037-2048 doi:10.1007/s40265-017-0849-3.

    PMID: 29177573
  14. 14

    Radiotherapy of breast cancer: 2025 update.

    Ghannam Y, Le Scodan R, Rivera S, et al.

    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 2025; (29(7-8)):104767 doi:10.1016/j.canrad.2025.104767.

    PMID: 41270649
  15. 15

    Triple-negative breast cancer and radiation therapy.

    de Faria Bessa J, Marta GN

    Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology 2022; (27(3)):545-551 doi:10.5603/RPOR.a2022.0025.

    PMID: 36186688
  16. 16

    Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.

    Park KU, Somerfield MR, Anne N, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(14)):1720-1741 doi:10.1200/JCO-25-00099.

    PMID: 40209128
  17. 17

    Regional Nodal Irradiation in Early-Stage Breast Cancer.

    Whelan TJ, Olivotto IA, Parulekar WR, et al.

    The New England journal of medicine 2015; (373(4)):307-16 doi:10.1056/NEJMoa1415340.

    PMID: 26200977
  18. 18

    Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series.

    Grossmith S, Nguyen A, Hu J, et al.

    Annals of surgical oncology 2018; (25(12)):3527-3534 doi:10.1245/s10434-018-6525-3.

    PMID: 29868979
  19. 19

    Axillary Management in Breast Cancer Patients: A Comprehensive Review of the Key Trials.

    Yan M, Abdi MA, Falkson C

    Clinical breast cancer 2018; (18(6)):e1251-e1259 doi:10.1016/j.clbc.2018.08.002.

    PMID: 30262257
  20. 20

    Bone health during endocrine therapy for cancer.

    Rachner TD, Coleman R, Hadji P, Hofbauer LC

    The lancet. Diabetes & endocrinology 2018; (6(11)):901-910 doi:10.1016/S2213-8587(18)30047-0.

    PMID: 29572126
  21. 21

    Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.

    Gnant M, Frantal S, Pfeiler G, et al.

    NEJM evidence 2022; (1(12)):EVIDoa2200162 doi:10.1056/EVIDoa2200162.

    PMID: 38319865

This page is for informational purposes only and does not constitute medical advice. Your breast oncology team can tailor treatment to your tumor biology, stage, menopausal status, and overall health.

Get notified when new evidence is published on female breast upper-outer quadrant cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.